248 related articles for article (PubMed ID: 10081853)
1. Long-term consequences from bladder perforation and/or violation in the presence of transitional cell carcinoma: results of a small series and a review of the literature.
Mydlo JH; Weinstein R; Shah S; Solliday M; Macchia RJ
J Urol; 1999 Apr; 161(4):1128-32. PubMed ID: 10081853
[TBL] [Abstract][Full Text] [Related]
2. Does the management of bladder perforation during transurethral resection of superficial bladder tumors predispose to extravesical tumor recurrence?
Skolarikos A; Chrisofos M; Ferakis N; Papatsoris A; Dellis A; Deliveliotis C
J Urol; 2005 Jun; 173(6):1908-11. PubMed ID: 15879773
[TBL] [Abstract][Full Text] [Related]
3. The actual incidence of bladder perforation following transurethral bladder surgery.
Balbay MD; Cimentepe E; Unsal A; Bayrak O; Koç A; Akbulut Z
J Urol; 2005 Dec; 174(6):2260-2, discussion 2262-3. PubMed ID: 16280794
[TBL] [Abstract][Full Text] [Related]
4. [Iatrogenic tumor cell implantation in bladder cancer].
Mack D; Rammal E; Jakse G
Urologe A; 1988 Mar; 27(2):99-104. PubMed ID: 3376373
[TBL] [Abstract][Full Text] [Related]
5. [Intestinal obstruction caused by transitional carcinoma].
Vesga Molina F; Blasco de Villalonga M; Albisu Tristan A; Llarena Ibarguren R; Pertusa Peña C
Arch Esp Urol; 1996 Mar; 49(2):177-9. PubMed ID: 8702331
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
[TBL] [Abstract][Full Text] [Related]
8. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
[TBL] [Abstract][Full Text] [Related]
9. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors.
Filbeck T; Pichlmeier U; Knuechel R; Wieland WF; Roessler W
J Urol; 2002 Jul; 168(1):67-71. PubMed ID: 12050494
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
Shariat SF; Karakiewicz PI; Palapattu GS; Lotan Y; Rogers CG; Amiel GE; Vazina A; Gupta A; Bastian PJ; Sagalowsky AI; Schoenberg MP; Lerner SP
J Urol; 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118
[TBL] [Abstract][Full Text] [Related]
11. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
[TBL] [Abstract][Full Text] [Related]
12. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
[TBL] [Abstract][Full Text] [Related]
13. Early complications of endoscopic treatment for superficial bladder tumors.
Collado A; Chéchile GE; Salvador J; Vicente J
J Urol; 2000 Nov; 164(5):1529-32. PubMed ID: 11025697
[TBL] [Abstract][Full Text] [Related]
14. Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors.
Chou EC; Lin AT; Chen KK; Chang LS
Int J Urol; 2006 Jun; 13(6):682-5. PubMed ID: 16834642
[TBL] [Abstract][Full Text] [Related]
15. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
[TBL] [Abstract][Full Text] [Related]
16. Urothelial carcinoma in both adnexa following perforation during transurethral resection of a non-muscle-invasive bladder tumor: a case report and literature review.
Bus MT; Cordeiro ER; Anastasiadis A; Klioueva NM; de la Rosette JJ; de Reijke TM
Expert Rev Anticancer Ther; 2012 Dec; 12(12):1529-36. PubMed ID: 23253219
[TBL] [Abstract][Full Text] [Related]
17. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.
Cho KS; Seo HK; Joung JY; Park WS; Ro JY; Han KS; Chung J; Lee KH
J Urol; 2009 Dec; 182(6):2625-30. PubMed ID: 19836779
[TBL] [Abstract][Full Text] [Related]
18. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
Brake M; Loertzer H; Horsch R; Keller H
J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
[TBL] [Abstract][Full Text] [Related]
19. P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer.
Ito M; Nishiyama H; Kawanishi H; Matsui S; Guilford P; Reeve A; Ogawa O
J Urol; 2007 Sep; 178(3 Pt 1):1073-9. PubMed ID: 17644138
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy.
Hassan JM; Cookson MS; Smith JA; Johnson DL; Chang SS
J Urol; 2004 Sep; 172(3):882-4. PubMed ID: 15310989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
